Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    August 2019
  1. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    PubMed     Text format    


  2. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Text format     Abstract available


  3. ZELNIKER TA, Wiviott SD, Raz I, Sabatine MS, et al
    SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
    Lancet. 2019;394:560-561.
    PubMed     Text format    


  4. STRANDBERG TE, Petrovic M, Benetos A
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:560.
    PubMed     Text format    


  5. MALAGA G, Ruiz EF
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:559-560.
    PubMed     Text format    


  6. BARNETT R
    Type 2 diabetes.
    Lancet. 2019;394:557.
    PubMed     Text format    


  7. HOORN EJ
    Testing the waters: a new test for hypotonic polyuria.
    Lancet. 2019;394:546-547.
    PubMed     Text format    


  8. LEVAILLANT M, Lievre G, Baert G
    Ending diabetes in Mexico.
    Lancet. 2019;394:467-468.
    PubMed     Text format    


    July 2019
  9. WINZELER B, Cesana-Nigro N, Refardt J, Vogt DR, et al
    Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study.
    Lancet. 2019 Jul 11. pii: S0140-6736(19)31255.
    PubMed     Text format     Abstract available


  10. HOLST JJ
    Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
    Lancet. 2019;394:4-6.
    PubMed     Text format    


    June 2019
  11. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Text format     Abstract available


  12. VERMA S, Mazer CD, Perkovic V
    Is it time to REWIND the cardiorenal clock in diabetes?
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31267.
    PubMed     Text format    


  13. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31150.
    PubMed     Text format     Abstract available


  14. PRATLEY R, Amod A, Hoff ST, Kadowaki T, et al
    Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31271.
    PubMed     Text format     Abstract available


    May 2019
  15. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.
    PubMed     Text format    


  16. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Text format     Abstract available


  17. GREGG EW, Cheng Y, Imperatore G
    Trend analysis of diabetic mortality - Authors' reply.
    Lancet. 2019;393:1932.
    PubMed     Text format    


  18. YUAN X, Song F, Zhang L
    Trend analysis of diabetic mortality.
    Lancet. 2019;393:1931-1932.
    PubMed     Text format    


  19. WATTS G
    Shitaye Alemu Balcha: committed to rural health care in Ethiopia.
    Lancet. 2019;393:1797.
    PubMed     Text format    


    April 2019
  20. ZHONG D, Yi Y, Lin C
    A kidney changes size: first increasing and then decreasing.
    Lancet. 2019;393:1641.
    PubMed     Text format    


  21. TUTTLE KR
    A turning point for chronic kidney disease in diabetes.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30855.
    PubMed     Text format    


  22. HEERSPINK HJL, Parving HH, Andress DL, Bakris G, et al
    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30772.
    PubMed     Text format     Abstract available


    March 2019
  23. THE LANCET
    Gestational diabetes in England: cause for concern.
    Lancet. 2019;393:1262.
    PubMed     Text format    


  24. EVANS ML, Golubic R
    Technology to overcome clinical inertia in insulin therapy.
    Lancet. 2019;393:1078-1080.
    PubMed     Text format    


  25. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    


  26. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    


  27. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    


  28. XIAO F, Liu M, Wang XF
    Involuntary choreiform movements in a diabetic patient.
    Lancet. 2019;393:1033.
    PubMed     Text format    


    February 2019
  29. BERGENSTAL RM, Johnson M, Passi R, Bhargava A, et al
    Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Lancet. 2019 Feb 22. pii: S0140-6736(19)30368.
    PubMed     Text format     Abstract available


    January 2019
  30. STEDMAN M, Lunt M, Livingston M, Fryer AA, et al
    The costs of drug prescriptions for diabetes in the NHS.
    Lancet. 2019;393:226-227.
    PubMed     Text format    


  31. THE LANCET
    Modernising the NHS: leading the way with diabetes.
    Lancet. 2019;393:200.
    PubMed     Text format    


  32. VERMA S, Juni P, Mazer CD
    Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    Lancet. 2019;393:3-5.
    PubMed     Text format    


    December 2018
  33. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Text format     Abstract available


  34. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed     Text format    


    November 2018
  35. UNAMUNO X, Fruhbeck G
    Lorcaserin: balancing efficacy with potential risks.
    Lancet. 2018;392:2239-2240.
    PubMed     Text format    


  36. STUMVOLL M, Tschop M
    Twice the benefits with twincretins?
    Lancet. 2018;392:2142-2144.
    PubMed     Text format    


  37. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available


    October 2018
  38. TAYLOR R, Adamson AJ, Sattar N, Lean MEJ, et al
    VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Lancet. 2018;392:1307.
    PubMed     Text format    


  39. AHMAD N, Alfaris N
    VLCD for weight loss and remission of type 2 diabetes?
    Lancet. 2018;392:1306-1307.
    PubMed     Text format    


  40. BOHULA EA, Scirica BM, Inzucchi SE, McGuire DK, et al
    Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32328.
    PubMed     Text format     Abstract available


  41. FRIAS JP, Nauck MA, Van J, Kutner ME, et al
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32260.
    PubMed     Text format     Abstract available


  42. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed     Text format    


  43. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Text format     Abstract available


  44. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available


  45. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    


    September 2018

  46. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.
    Lancet. 2018;392:1072-1088.
    PubMed     Text format     Abstract available


    August 2018
  47. KLUGER AY, McCullough PA
    Semaglutide and GLP-1 analogues as weight-loss agents.
    Lancet. 2018;392:615-616.
    PubMed     Text format    


  48. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available


  49. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed     Text format    


  50. MCCALL C
    Biosimilars for insulin: a cost-saving alternative?
    Lancet. 2018;392:463-464.
    PubMed     Text format    


    July 2018
  51. PALMER SC, Strippoli GFM
    Metformin as first-line treatment for type 2 diabetes.
    Lancet. 2018;392:120.
    PubMed     Text format    


    June 2018
  52. RAYNER CK, Horowitz M
    Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30936.
    PubMed     Text format    


  53. AMBERY P, Parker VE, Stumvoll M, Posch MG, et al
    MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30726.
    PubMed     Text format     Abstract available


  54. LANGENBERG C, Lotta LA
    Genomic insights into the causes of type 2 diabetes.
    Lancet. 2018;391:2463-2474.
    PubMed     Text format     Abstract available


  55. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Text format     Abstract available


  56. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    


  57. STEYN M, Couchman L, Coombes G, Earle KA, et al
    A herbal treatment for type 2 diabetes adulterated with undisclosed drugs.
    Lancet. 2018;391:2411.
    PubMed     Text format    


  58. THE LANCET
    Untangling the complications of diabetes.
    Lancet. 2018;391:2389.
    PubMed     Text format    


    May 2018
  59. BENNETT PH
    Diabetes mortality in the USA: winning the battle but not the war?
    Lancet. 2018 May 18. pii: S0140-6736(18)30843.
    PubMed     Text format    


  60. GREGG EW, Cheng YJ, Srinivasan M, Lin J, et al
    Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
    Lancet. 2018 May 18. pii: S0140-6736(18)30314.
    PubMed     Text format     Abstract available


    March 2018
  61. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed     Text format    


  62. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed     Text format    


  63. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed     Text format    


    February 2018
  64. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed     Text format    


  65. SARHAN MB, Ghandour R, Rmeileh NMEA
    The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study.
    Lancet. 2018;391 Suppl 2:S30.
    PubMed     Text format     Abstract available


  66. SAMAN KA, Massad S, Ibaid AA, Anan H, et al
    Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.
    Lancet. 2018;391 Suppl 2:S19.
    PubMed     Text format     Abstract available


  67. CANALI G, Tittle V, Seita A
    Medication adherence by Palestine refugees living in Jordan who have diabetes: a cross-sectional study.
    Lancet. 2018;391 Suppl 2:S13.
    PubMed     Text format     Abstract available


  68. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed     Text format    


  69. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Text format     Abstract available


    January 2018
  70. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed     Text format    


    December 2017
  71. UUSITUPA M
    Remission of type 2 diabetes: mission not impossible.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33100.
    PubMed     Text format    


  72. LEAN ME, Leslie WS, Barnes AC, Brosnahan N, et al
    Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33102.
    PubMed     Text format     Abstract available


    November 2017
  73. BROWN DM, Wykoff CC
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2141.
    PubMed     Text format    


  74. SIVAPRASAD S, Prevost AT, Vasconcelos J, Riddell A, et al
    Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
    Lancet. 2017;390:2141-2142.
    PubMed     Text format    


  75. LIU L, Tham YC, Cheng CY
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2140-2141.
    PubMed     Text format    


    October 2017
  76. MCGAVOCK J, Wicklow B, Dart AB
    Type 2 diabetes in youth is a disease of poverty.
    Lancet. 2017;390:1829.
    PubMed     Text format    


    September 2017
  77. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed     Text format    


  78. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Text format     Abstract available


  79. JEFFCOATE W, Barron E, Lomas J, Valabhji J, et al
    Using data to tackle the burden of amputation in diabetes.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32401.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: